MOA: this antigen overcome tumor escape from the immune system by using a novel process mechanism independent of TAP/ Proteasome pathway/

Route of administration: Intra dermal injection

Used in combination with a marketed vaccine adjuvant

API & DP produced by CMO FDA / EMA approved

Market

For decades, lung cancer has been the leading cause of cancer death in the world. Despite the possibilities of surgery and chemo- or radio-therapy treatments, only 15% of patients are still alive two years after diagnosis. Therefore lung cancer represents both a medical challenge and a socio-economic problem at the forefront of public health in Europe and the United States. ElyssaMed® will primarily target the cancer drug market. This market reached 60 billion Euro in 2012, including 6 billion in France. Its growth, estimated at 10.8% per year, is twice as fast as that of the entire pharmaceutical market.

The first cancer that will be targeted by the ElyssaMed® technology is the non-small cell lung cancer which account for 80% of lung cancers. However, the team's research studies have shown that other cancers could be targeted by the vaccine including medullary thyroid cancers (MTC), neuroendocrine tumors (NET) and small cell lung cancers (SCLC) as well as all tumors that express PPCT.

The latter pathologies include those that are classified as rare (orphan) diseases for which a facilitated and accelerated development of new treatments is permitted.